BioXcel Therapeutics (BTAI) Current Assets (2017 - 2026)

BioXcel Therapeutics' Current Assets history runs 10 years deep, the most recent figure standing at $33.9 million for Q1 2026.

• On a quarterly basis, Current Assets fell 10.24% year-over-year to $33.9 million in Q1 2026; TTM through Mar 2026 was $33.9 million, a 10.24% decrease from a year earlier, with the FY2025 full-year figure at $44.7 million, up 19.5% from the prior year.
• Current Assets retreated to $33.9 million in Q1 2026 per BTAI's latest filing, from $44.7 million in the prior quarter.
• Across five years, Current Assets topped out at $244.9 million in Q2 2022 and bottomed at $25.2 million in Q2 2025.
• The 5-year median for Current Assets is $72.1 million (2023), against an average of $105.9 million.
• Across the five-year window, Current Assets slumped 64.44% in 2023 and rose 19.5% in 2025, its largest moves.
• Year by year, Current Assets stood at $202.9 million in 2022, then slumped by 64.44% to $72.1 million in 2023, then plunged by 48.17% to $37.4 million in 2024, then advanced by 19.5% to $44.7 million in 2025, then retreated by 24.12% to $33.9 million in 2026.
• Per Business Quant, the three latest BTAI Current Assets figures stand at $33.9 million (Q1 2026), $44.7 million (Q4 2025), and $44.4 million (Q3 2025).